Inasmuch as activated FcγRIIlow/− B cells in HCC tumours potently correlated with disease progression and even produced protumorigenic IL-10 (Fig. 1d,f), we investigated whether FcγRIIlow/− B cells affected CD8+ cytotoxic T-cell immunity in tumours. This evidence concerns the gene CD8A and hepatocellular carcinoma.